PUBLISHER: Grand View Research | PRODUCT CODE: 1771483
PUBLISHER: Grand View Research | PRODUCT CODE: 1771483
U.S. Aorto-iliac Occlusive Disease Treatment Market Size, Share & Trends Analysis Report By Device Type, By Procedure, By End-use, And Segment Forecasts, 2025 - 2030
Market Size & Trends:
The U.S. aorto-iliac occlusive disease (iliac disease) treatment market size was estimated at USD 716.6 million in 2024 and is projected to grow at a CAGR of 5.4% from 2025 to 2030. Increasing PAD incidence, rising government initiatives, and technological advancements drive market growth. For instance, in November 2024, Philips recently launched the THOR IDE clinical trial in the U.S. to evaluate a novel hybrid catheter system that combines laser atherectomy and intravascular lithotripsy.
The device is designed to treat severely calcified lesions commonly found in PAD and aorto-iliac disease. The first successful patient procedure, conducted at the Cardiovascular Institute of the South in Louisiana, demonstrates the potential for this device to streamline complex interventions and improve procedural outcomes. Increasing government initiatives drive market growth. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs.
Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, which are critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.
The proliferation of ambulatory surgical centers (ASCs) and office-based labs (OBLs) across the U.S. significantly contributes to the growth in procedural volumes for vascular interventions, including those for aorto-iliac occlusive disease. These facilities offer a cost-effective and convenient alternative to traditional hospital settings, enabling quicker patient turnaround, reduced overhead costs, and enhanced scheduling flexibility for both patients and physicians. As a result, iliac artery interventions-such as balloon angioplasty, stenting, and atherectomy are increasingly being performed in ASCs and OBLs, especially for patients presenting with early to moderate stages of the disease. These minimally invasive procedures can often be completed on an outpatient basis, making them well-suited to these settings where shorter recovery times and lower procedural risk are prioritized. The shift toward these centers is also supported by favorable reimbursement policies, making them a preferred site of care for providers and payers.
U.S. Aorto-iliac Occlusive Disease Treatment Market Report Segmentation
This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aorto-iliac occlusive disease (iliac disease) treatment market report based on device type, procedure, and end-use:
- Device Type Outlook (Revenue, USD Million, 2018 - 2030)
- Endovascular Devices
- Balloon Angioplasty Devices
- Atherectomy Systems
- Stents
- Self-Expanding Stents
- Balloon-Expandable Stents
- Covered Stent Grafts
- Bifurcated Aortic Stent Grafts
- Surgical Devices
- Procedure Outlook (Revenue, USD Million, 2018 - 2030)
- Endovascular Procedures
- Balloon Angioplasty
- Primary Stenting
- Kissing Stents
- Covered Stent Grafts
- Endovascular Aortic Repair (EVAR)
- Hybrid Procedures
- Open Surgical Procedures
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Outpatient Facilities
- Others
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Device Type
- 1.2.2. Procedure
- 1.2.3. End Use
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Volume price analysis (Model 1)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Device Type outlook
- 2.2.2. Procedure outlook
- 2.2.3. End Use outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising prevalence of peripheral artery disease (PAD)
- 3.2.1.2. Advancements in endovascular technologies
- 3.2.1.3. Shift towards in minimally invasive procedures
- 3.2.2. Market restraint analysis
- 3.2.2.1. Product recalls
- 3.2.2.2. Clinical complexity and procedural risks
- 3.2.1. Market driver analysis
- 3.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.1. Industry Analysis - Porter's
Chapter 4. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Estimates & Trend Analysis
- 4.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Dashboard
- 4.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Movement Analysis
- 4.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Device Type, Revenue
- 4.4. Endovascular Devices
- 4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.2. Balloon Angioplasty Devices
- 4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.3. Atherectomy Systems
- 4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.4. Stents
- 4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.4.2. Self-expanding Stents
- 4.4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.4.3. Balloon-expandable Stents
- 4.4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.4.4. Covered stent grafts
- 4.4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.4.5. Bifurcated aortic stent grafts
- 4.4.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.5. Surgical Devices
- 4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Estimates & Trend Analysis
- 5.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Dashboard
- 5.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Movement Analysis
- 5.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Procedure, Revenue
- 5.4. Endovascular Procedures
- 5.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.2. Balloon Angioplasty
- 5.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.3. Primary Stenting
- 5.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.4. Kissing Stents
- 5.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.5. Covered Stent Grafts
- 5.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.6. Endovascular Aortic Repair (EVAR)
- 5.4.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.5. Hybrid Procedures
- 5.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.6. Surgical Procedures
- 5.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Estimates & Trend Analysis
- 6.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Dashboard
- 6.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Movement Analysis
- 6.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by End Use, Revenue
- 6.4. Hospitals
- 6.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 6.5. Outpatient Facilities
- 6.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. Key company market share analysis, 2024
- 7.4. Company Profiles
- 7.4.1. BD
- 7.4.1.1. Company overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. Abbott
- 7.4.2.1. Company overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Boston Scientific Corporation
- 7.4.3.1. Company overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. W. L. Gore & Associates, Inc.
- 7.4.4.1. Company overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. Medtronic
- 7.4.5.1. Company overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. Cook
- 7.4.6.1. Company overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. Terumo Corporation
- 7.4.7.1. Company overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. Getinge AB
- 7.4.8.1. Company overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.1. BD
List of Tables
- Table 1 List of Abbreviations
- Table 2 List of secondary sources
- Table 3 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by device type, 2018 - 2030 (USD Million)
- Table 4 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by procedure, 2018 - 2030 (USD Million)
- Table 5 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by end use, 2018 - 2030 (USD Million)
- Table 6 Participant's overview
- Table 7 Financial performance
- Table 8 Key companies undergoing expansions
- Table 9 Key companies undergoing acquisitions
- Table 10 Key companies undergoing collaborations
- Table 11 Key companies launching new services
- Table 12 Key companies undergoing partnerships
- Table 13 Key companies undertaking other strategies
List of Figures
- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Market formulation & validation
- Fig. 6 U.S. aorto-iliac occlusive disease (iliac disease) treatment market segmentation
- Fig. 7 Market snapshot, 2024
- Fig. 8 Market trends & outlook
- Fig. 9 Market driver relevance analysis (current & future impact)
- Fig. 10 Market restraint relevance analysis (current & future impact)
- Fig. 11 Swot analysis, by factor (political & legal, economic, and technological)
- Fig. 12 Porter's five forces analysis
- Fig. 13 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Outlook Key Takeaways
- Fig. 14 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Movement Analysis
- Fig. 15 Endovascular devices market, 2018 - 2030 (USD Million)
- Fig. 16 Balloon angioplasty devices market, 2018 - 2030 (USD Million)
- Fig. 17 Atherectomy systems market, 2018 - 2030 (USD Million)
- Fig. 18 Stents market, 2018 - 2030 (USD Million)
- Fig. 19 Self-expanding stents market, 2018 - 2030 (USD Million)
- Fig. 20 Balloon-expandable stents market, 2018 - 2030 (USD Million)
- Fig. 21 Covered stent grafts market, 2018 - 2030 (USD Million)
- Fig. 22 Bifurcated aortic stent grafts market, 2018 - 2030 (USD Million)
- Fig. 23 Surgical devices market, 2018 - 2030 (USD Million)
- Fig. 24 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure outlook key takeaways
- Fig. 25 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure movement analysis
- Fig. 26 Endovascular procedures market, 2018 - 2030 (USD Million)
- Fig. 27 Balloon angioplasty market, 2018 - 2030 (USD Million)
- Fig. 28 Primary stenting market, 2018 - 2030 (USD Million)
- Fig. 29 Kissing stents market, 2018 - 2030 (USD Million)
- Fig. 30 Covered stent grafts market, 2018 - 2030 (USD Million)
- Fig. 31 Endovascular aortic repair (EVAR) market, 2018 - 2030 (USD Million)
- Fig. 32 Hybrid procedures market, 2018 - 2030 (USD Million)
- Fig. 33 Open surgical procedures market, 2018 - 2030 (USD Million)
- Fig. 34 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use outlook key takeaways
- Fig. 35 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use movement analysis
- Fig. 36 Hospitals market, 2018 - 2030 (USD Million)
- Fig. 37 Outpatient facilities market, 2018 - 2030 (USD Million)
- Fig. 38 Others market, 2018 - 2030 (USD Million)
- Fig. 39 Strategy framework
